97455-61-3

Usage

Uses

Used in Chemical Synthesis:
3-Pyridinecarboxaldehyde, 6-ethoxy(9CI) is used as a building block for the synthesis of other organic compounds. Its unique structure and the presence of the 6-ethoxy group contribute to its specific reactivity, making it a valuable component in the creation of a wide range of chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-Pyridinecarboxaldehyde, 6-ethoxy(9CI) is used as a key intermediate in the development of new drugs. Its unique chemical properties and reactivity allow for the design and synthesis of novel pharmaceutical compounds with potential therapeutic applications.
Used in Agrochemical Industry:
3-Pyridinecarboxaldehyde, 6-ethoxy(9CI) also finds applications in the agrochemical industry, where it is used as a starting material for the synthesis of various agrochemicals. Its unique structure and reactivity enable the development of new agrochemicals with improved efficacy and selectivity.

InChI:InChI=1/C8H9NO2/c1-2-11-8-4-3-7(6-10)5-9-8/h3-6H,2H2,1H3

Upstream product

• 55849-30-4 5-bromo-2-ethoxypyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 31594-45-3 2-ethoxy-5-nitropyridine 
• 97455-65-7 6-ethoxy-3-pyridinecarboxylic acid 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 85259-10-5 (E)-3-(6-Ethoxy-pyridin-3-yl)-acrylic acid 

Downstream Products

• 265114-31-6 5-(6-ethoxy-3-pyridyl)-1-(4-methylsulfonylphenyl)imidazole 

Relevant academic research and scientific papers

Novel indirect AMP-activated protein kinase activators: Identification of a second-generation clinical candidate with improved physicochemical properties and reduced hERG inhibitory activity

This study reports the synthesis and evaluation of novel indirect AMP-activated protein kinase (AMPK) activators. The series of compounds selectively inhibited cell growth in several human breast cancer cell lines by activating AMPK. We performed back-up medicinal chemistry synthetic research on ASP4132, a previously reported as a compound for clinical development that acts as an indirect AMPK activator. This led to the successful identification of 4-({4-[5-({1-[(5-ethoxypyrazin-2-yl)methyl]-4-fluoropiperidin-4-yl}methoxy)-3-methylpyridine-2-carbonyl]piperazin-1-yl}methyl)benzonitrile succinate (27b), a potent, highly aqueous soluble and metabolically stable compound in human hepatocytes. Compound 27b also showed weaker human Ether-a-go-go Related Gene (hERG) inhibitory activity than that of compound 13 and ASP4132. Therefore, 27b was a promising AMPK activator and a second-generation clinical candidate for treatment for human cancer.

TRICYCLIC PIPERIDINE COMPOUNDS

The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acc

6-n-Alkoxy-3-Pyridinecarboxaldehydes: New Intermediates to Liquid Crystals. Properties of Some Derivatives.

The synthesis of new intermediates to liquid crystals, a series of 6-n-alkoxy-3-pyridinecarboxaldehydes is described.The mesomorphic properties of their precursors, the 6-n-alkoxy-3-pyridinecarboxylic acids are reported.Some derivatives of the carboxaldeh